
iStock.com/Volha Barysevich
Statement on FDA Removal of Blackbox Warnings on Estrogen-Based Hormone Therapy Products for Menopause
Nov 11, 2025
Nov 11, 2025
Women's Health Policy
Beth brings a unique combination of sharp business expertise and women's health insight to her leadership of the organization. Beth has worked in the health care industry for more than 25 years helping to define and drive public education programs on a broad range of women's health issues. She launched and has expanded the HealthyWomen.org brand. As a result of her leadership, HealthyWomen was recognized as one of the top 100 women's health web sites by Forbes for three consecutive years, and was recognized by Oprah magazine as one of the top women's health web sites. HealthyWomen now connects to millions of women across the country through its wide program distribution and innovative use of technology.
Beth is responsible for the business development and strategic positioning of HealthyWomen. She creates partnerships with key health care professionals and consumer groups to provide strategic, engaging and informative award-winning programs. She serves as the organization's chief spokesperson, regularly participating in corporate, non-profit, community and media events. She also is a practicing nurse in maternal child health at Riverview Medical Center- Hackensack Meridian Health, in Red Bank, NJ.
In addition to her nursing degree, Beth holds degrees in political science, business and public administration from Marymount University.
To stay sane, she loves to run and compete in road races. She enjoys skiing and sailing with her husband and young son, and welcoming new babies into the world.
Full BioLearn about our editorial policies

As a leading voice in women’s midlife health, HealthyWomen recognizes the important step taken by the FDA to improve access to hormone therapy (HT) products for women experiencing perimenopausal and menopausal symptoms by modifying the black box warning labels for estrogen products.
Since 2003, the blackbox warning on low-dose vaginal estrogen products has had a chilling effect on patients and clinicians alike, undermining the use of this proven treatment for genitourinary syndrome of menopause. HealthyWomen is proud to have called for the removal of this blackbox warning on low-dose vaginal estrogen products alongside many other women’s health organizations. The evidence in favor of the safety and efficacy for low-dose vaginal estrogen is robust, and HealthyWomen celebrates the FDA’s move to align medication labeling with current scientific evidence.
Regarding systemic hormone therapies, which are more readily absorbed into the bloodstream, and have different safety profiles than vaginal estrogen, HealthyWomen will continue to encourage patients to connect with their healthcare providers to determine the best treatment for their menopause journey.
Overall, HealthyWomen commends this demonstrated action to improve care for women and remains steadfast in its mission to educate women to make informed health decisions, to advocate for themselves and to prioritize their health and wellness.
Everything You Ever Wanted to Know About Vaginal Estrogen
More Research Shows Vaginal Estrogen Is Safe for People with a History of Breast Cancer